Triple threat: new combo aims to stop lung cancer in its tracks
NCT ID NCT03141359
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This phase II trial tests a three-step approach for stage II or III non-small cell lung cancer. First, the main tumor gets a high-dose radiation blast (SBRT). Then, the chest lymph nodes receive standard radiation plus chemotherapy. Finally, patients get an immunotherapy drug (durvalumab) to help prevent the cancer from coming back. The study enrolled 61 people and is now following them to see how many are alive without cancer progression after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (immunotherapy), Carboplatin, Paclitaxel, Cisplatin, Etoposide (chemotherapy), and radiation therapy (SBRT, IMRT)
- What this could lead to
- If successful, this combination approach could improve the chance of keeping lung cancer from growing or returning for at least a year.
- What could go wrong
- This is a small, single-arm Phase II trial, so results may not apply broadly. Side effects from radiation, chemotherapy, and immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?